Fatty15 vs Fish Oil: Which Fatty Acid Supplement Do You Actually Need?
Fatty15 and fish oil are both “healthy fat” supplements, so it’s natural to wonder whether one replaces the other. They don’t. Fatty15 delivers C15 (pentadecanoic acid), an odd-chain saturated fatty acid; fish oil delivers omega-3s (EPA and DHA), long-chain polyunsaturated fats. They are different molecules with different roles, and the honest answer is that they complement each other more than they compete.
The Core Difference
Fish oil’s omega-3s are best known for cardiovascular and anti-inflammatory support and are among the most-studied supplements in the world. C15 is a newer focus, researched for cell-membrane stability and metabolic and liver markers. One is a decades-established staple; the other is a newcomer with early and mixed evidence [1][2][3].
Research note: The omega-3 index (EPA+DHA in red blood cell membranes) is described as a measurable marker that predicts cardiovascular mortality, a validated target pentadecanoic acid does not have [8].
Fatty15 vs Fish Oil: Side-by-Side
| Fatty15 (C15) | Fish Oil (Omega-3) | |
|---|---|---|
| Fatty acid type | Odd-chain saturated (C15) | Long-chain polyunsaturated (EPA/DHA) |
| Main research focus | Cell membranes, metabolic & liver markers | Heart, triglycerides, inflammation, brain |
| Evidence base | Early and mixed [1][2] | Extensive, with mixed results |
| Source | Synthesized and vegan-friendly (FA15); C15 also occurs in trace amounts in dairy and some fish | Fish or algae |
| Common issue | No common issue verified | Fishy aftertaste/burps |
Does Fatty15 Replace Fish Oil?
No. Fatty15 does not provide omega-3s, so it cannot deliver the specific EPA/DHA benefits fish oil is taken for. If your reason for taking fish oil is omega-3 intake (heart, triglycerides, brain), Fatty15 is not a substitute. Conversely, fish oil does not provide C15. The marketing that positions C15 as a “next-generation” fat doesn’t mean it does the same job as omega-3.
Should You Take Both?
Many people reasonably take both, omega-3s for their triglyceride-lowering evidence and C15 for its distinct membrane and metabolic research. There’s no known conflict. If budget forces a choice, decide by goal: omega-3 if your goal is lowering triglycerides, C15 if you’re specifically interested in the pentadecanoic acid research.
If you do want C15, you can get the molecule without the premium brand, see our Fatty15 alternatives, and our Fatty15 review for whether the branded version is worth it.
What the Big Fish Oil Trials Actually Found
The comparison table on this page calls fish oil’s evidence base extensive, which is fair, but the results are more mixed than the word established suggests, and a reader choosing between the two deserves the detail.
- REDUCE-IT (New England Journal of Medicine, 2019). This trial gave 8,179 patients already on statins, with elevated triglycerides, either 4 g a day of icosapent ethyl (a highly purified EPA ester) or placebo. Over a median 4.9 years the primary composite of cardiovascular events was 17.2 percent versus 22.0 percent (hazard ratio 0.75). Hospitalization for atrial fibrillation or flutter was higher on the drug (3.1 percent versus 2.1 percent), and serious bleeding was 2.7 versus 2.1 percent, a difference that did not reach significance. This was a prescription-grade product in a high-risk group, not a typical over-the-counter fish oil.
- VITAL (New England Journal of Medicine, 2019). In 25,871 older adults at usual risk, 1 g a day of marine omega-3s did not significantly lower major cardiovascular events (hazard ratio 0.92, confidence interval 0.80 to 1.06) or cancer. Total myocardial infarction was lower (hazard ratio 0.72), a secondary finding.
- Cochrane review (2020). Pooling 86 randomized trials and 162,796 participants, the review found little or no effect of increasing long-chain omega-3 on all-cause mortality or cardiovascular events, and possible slight reductions in coronary heart disease mortality and events with low-certainty evidence. Omega-3 did reduce triglycerides by about 15 percent in a dose-dependent way, with high-certainty evidence.
So the strongest, most consistent effect of omega-3 supplements is on triglycerides, while heart-protection benefits depend on dose, product and who is taking it. That is still a far larger body of randomized evidence than exists for C15.
What Is Known So Far About C15
Pentadecanoic acid is a saturated fat, which surprises people who assume all saturated fats behave alike. The C15 literature is smaller and earlier. A 2020 paper in Scientific Reports (Venn-Watson, Lumpkin and Dennis, authors linked to the C15 supplement maker) combined [4] animal and cell experiments with population data, reporting that C15 attenuated inflammation, anemia, dyslipidemia and fibrosis in animals, and proposed it as a potential essential fatty acid while stating that further studies are needed. A 2024 randomized trial in the Journal of Nutrition (Robinson et al.) is the first supplementation trial in humans: 30 young adults with overweight or obesity took 200 mg a day for 12 weeks, circulating C15 rose 1.88 micrograms per mL more than on placebo, and no significant adverse events occurred. The trial was supported by Seraphina Therapeutics, which supplied the capsules [3]. A 2024 trial in the American Journal of Clinical Nutrition (TANGO) added C15 to a Mediterranean-style diet in 88 women with fatty liver and found an extra LDL-cholesterol reduction beyond the diet alone, while many other markers improved in all groups alongside weight loss.
Notably, Fatty15’s own FAQ describes C15 as the first essential fatty acid discovered in 90 years, adding that there are only two others, one omega-3 and one omega-6. That framing is an argument that C15 fills a different gap, not that it replaces omega-3. Whether it is truly essential is still debated, partly because research shows the body can make some odd-chain fatty acids from gut-derived propionate (a 2017 crossover study in 16 people raised plasma C15 by about 17 percent with inulin).
The fiber route is itself disputed. Two small human studies found that fiber supplements or a high-fiber diet did not raise circulating odd-chain fatty acids, and in Dutch heart attack survivors pentadecanoic acid tracked dairy intake but not fiber. An independent mini-review calls the essentiality of pentadecanoic acid controversial [5][6][7].
Where the Biology Overlaps and Where It Does Not
Review work by Philip Calder (Biochemical Society Transactions, 2017) explains how EPA and DHA act: they alter cell membrane phospholipid composition, disrupt lipid rafts, inhibit the NF-kappa B inflammatory switch and give rise to resolution mediators called resolvins, protectins and maresins. C15 is proposed to act through different routes, including partial activation of PPAR alpha and delta, AMPK activation, mTOR suppression and HDAC6 inhibition, according to a 2025 mechanism review in the World Journal of Biological Chemistry. Both are described as anti-inflammatory, but through different molecules and receptors, which supports the idea that one does not stand in for the other.
A company-linked cell screen found C15:0 shared 12 activities with EPA and added 28 more
In cells, C15:0 and fish-oil EPA overlap and differ, but no trial in people has compared them.
12 primary human cell-based systems. Authors are linked to a company that sells C15:0; counts of lab activities are not health benefits. Source: PLoS ONE 2022.
Data table
| Item | Value |
|---|---|
| Clinically relevant activities shared at 17 µM | 12activities |
| Additional activities seen only with C15:0 | 28activities |
Chart: c15hub.com: A company-linked cell screen found C15:0 shared 12 activities with EPA and added 28 more
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
A 2022 PLOS One paper (Venn-Watson and Butterworth) compared pure C15 with EPA across twelve primary human cell systems. C15 was non-cytotoxic at all concentrations, while EPA was cytotoxic in four systems at the highest concentration, 50 micromolar. These are cell experiments at concentrations that do not map neatly onto a capsule, and the authors are affiliated with the company that sells C15, so the title’s claim of safer activity should not be read as a head-to-head result in people.
A Practical Way to Think About Taking Both
Because the two supplements are different molecules with different evidence, the useful question is not which is better, but which question you are trying to answer for yourself.
- Dose is not interchangeable. Fatty15’s product page lists 100 mg of C15 per capsule and suggests starting with one or two capsules. The trial doses of omega-3 were 1 g a day in VITAL and 4 g in REDUCE-IT, so these are not like-for-like quantities of anything.
- Cost compounds. Fatty15 sits at the premium end of supplements, even on subscription. That is on top of whatever you already spend on omega-3.
- Check the reason you take fish oil. If you take it for triglycerides, the evidence supports it. If you take it hoping for general heart protection, the trials suggest modest or uncertain effects at supplement doses.
- Tell your clinician. High-dose omega-3 had a higher atrial fibrillation signal in REDUCE-IT and a bleeding signal that did not reach significance, which matters if you take blood thinners.
None of this makes C15 a substitute. It makes the comparison a question of which evidence you value: a mature but mixed literature for omega-3 versus an early, promising and still thin one for C15.
It is also worth separating food from capsules. People often get EPA and DHA from oily fish, while C15 appears in trace amounts in dairy fat and some fish. The trial evidence discussed here is almost entirely about supplements, so it says little about whether eating more fish or dairy has the same effect. If your main goal is a heart-healthy pattern, your overall diet will matter more than either capsule, and a clinician or dietitian can help you weigh that against supplement spending.
Want the detail behind the numbers? See the C15:0 vs omega-3 cell study, explained.
Frequently Asked Questions
Is Fatty15 better than fish oil?
Neither is “better”, they contain different fatty acids and do different things. Fish oil provides omega-3s (best supported for lowering triglycerides, with more mixed results for heart events); Fatty15 provides C15 for membrane and metabolic research. They complement rather than replace each other.
Can Fatty15 replace my omega-3 supplement?
No. Fatty15 contains no omega-3 (EPA/DHA), so it can’t deliver those specific benefits. If you take fish oil for omega-3s, keep it; Fatty15 is a separate addition, not a swap.
Should I take Fatty15 and fish oil together?
There’s no known interaction, and they target different systems, so taking both is common and reasonable. Check each product’s label for timing; Fatty15 says its capsules can be taken with or without food.
Does Fatty15 have omega-3?
No. Fatty15’s only ingredient is C15 (pentadecanoic acid), a saturated fatty acid, not an omega-3.
Do the large fish oil trials mean omega-3 does not work?
Not exactly. The Cochrane review found little or no effect on all-cause mortality and cardiovascular events, but a clear triglyceride reduction of about 15 percent, and REDUCE-IT showed a benefit for a high-dose purified EPA drug in high-risk patients. Results depend on the dose, product and population.
Is the evidence for C15 as strong as the evidence for fish oil?
No. Fish oil has dozens of large randomized trials. C15 has a small randomized trial of 30 people, a trial of 88 women where it was one component of a diet, and a larger body of cell and animal work.
Why do people say C15 is safer than EPA?
That comes from a cell-based study in which EPA was cytotoxic in four of twelve human cell systems at 50 micromolar while C15 was not. It is a laboratory comparison by authors affiliated with the C15 company, not a comparison of capsules in people.
References
- Venn-Watson S et al. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential? Scientific reports (2020). PMID 32424181
- Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society transactions (2017). PMID 28900017
- Bhatt DL et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England journal of medicine (2019). PMID 30415628
- Manson JE et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. The New England journal of medicine (2019). PMID 30415637
- Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. The Cochrane database of systematic reviews (2020). PMID 32114706
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Chooi YC et al. Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial. The American journal of clinical nutrition (2024). PMID 38035997
- Mercola J Molecular and cellular mechanisms of pentadecanoic acid. World journal of biological chemistry (2025). PMID 41378251
- Venn-Watson SK et al. Broader and safer clinically-relevant activities of pentadecanoic acid compared to omega-3: Evaluation of an emerging essential fatty acid across twelve primary human cell-based disease systems. PloS one (2022). PMID 35617322
- Weitkunat K et al. Odd-chain fatty acids as a biomarker for dietary fiber intake: a novel pathway for endogenous production from propionate. The American journal of clinical nutrition (2017). PMID 28424190
Related: Fatty15 vs NMN & NAD+ · Fatty15 Review · Fatty15 Alternatives
References
- Chen X et al. Lipid biomarkers for the prediction of type 2 diabetes risk, an umbrella review and updated meta-analyses of prospective observational studies. Frontiers in endocrinology (2026). PMID 42181198
- Brian T. Steffen et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in Nutrition (2026). PMID 41743064
- Robinson MK et al. Pentadecanoic Acid Supplementation in Young Adults with Overweight and Obesity: A Randomized Controlled Trial. The Journal of nutrition (2024). PMID 39069269
- Stephanie K Venn-Watson et al. Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?. Scientific Reports (2020). PMID 32424181
- Wu Y et al. Odd Chain Fatty Acids Are Not Robust Biomarkers for Dietary Intake of Fiber. Molecular nutrition & food research (2021). PMID 34605164
- Kamalita Pertiwi et al. Associations of dairy and fiber intake with circulating odd-chain fatty acids in post-myocardial infarction patients. Nutrition & Metabolism (2019). PMID 31754368
- Ciesielski V et al. New insights on pentadecanoic acid with special focus on its controversial essentiality: A mini-review. Biochimie (2024). PMID 39395658
- Michael R. Flock et al. Determinants of Erythrocyte Omega‐3 Fatty Acid Content in Response to Fish Oil Supplementation: A Dose-Response Randomized Controlled Trial. Journal of the American Heart Association (2013). PMID 24252845
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.